Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy

被引:20
作者
De Luca, A
Di Giambenedetto, S
Romano, L
Gonnelli, A
Corsi, P
Baldari, M
Di Pietro, M
Menzo, S
Francisci, D
Almi, P
Zazzi, M
机构
[1] Catholic Univ Rome, Clin Infect Dis, Rome, Italy
[2] Univ Siena, Virol Unit, I-53100 Siena, Italy
[3] Univ Siena, Infect Dis Unit, I-53100 Siena, Italy
[4] Univ Siena, Dept Mol Biol, I-53100 Siena, Italy
[5] SM Annunziata Hosp, Infect Dis Unit, Florence, Italy
[6] Grosseto Hosp, Infect Dis Unit, Grosseto, Italy
[7] Univ Ancona, Dept Microbiol, I-60128 Ancona, Italy
[8] Perugia Hosp, Dept Infect Dis, Perugia, Italy
[9] Massa Hosp, Infect Dis Unit, Massa, Italy
关键词
D O I
10.1086/502976
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated, in patients tested between 1991 and 2004, the patterns of mutually exclusive human immunodeficiency virus-1 thymidine-analogue mutations (TAMs) in 4039 reverse-transcriptase sequences with >= 1 TAM. TAM pattern 1, which included M41L and L210W and excluded K70R and is coupled with more-extensive cross-resistance to drugs, became the most frequent pattern after 1996. In 1465 genotypes from 684 patients in whom highly active antiretroviral therapy ( HAART) was unsuccessful, predictors of this pattern were the number of previous HAART regimens undergone ( adjusted odds ratio [ OR], 1.09 [ 95% confidence interval {CI}, 1.02-1.16]), use of stavudine/lamivudine (adjusted OR, 1.42 [ 95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [ 95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [ 95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [ 95% CI, 1.04-1.75]).
引用
收藏
页码:1219 / 1222
页数:4
相关论文
共 14 条
[1]   ORDERED APPEARANCE OF ZIDOVUDINE RESISTANCE MUTATIONS DURING TREATMENT OF 18 HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE SUBJECTS [J].
BOUCHER, CAB ;
OSULLIVAN, E ;
MULDER, JW ;
RAMAUTARSING, C ;
KELLAM, P ;
DARBY, G ;
LANGE, JMA ;
GOUDSMIT, J ;
LARDER, BA .
JOURNAL OF INFECTIOUS DISEASES, 1992, 165 (01) :105-110
[2]  
Brun-Vézinet F, 2003, AIDS, V17, P1795, DOI [10.1097/00002030-200308150-00008, 10.1097/01.aids.0000072669.21517.db]
[3]   A survival method to estimate the time to occurrence of mutations:: An application to thymidine analogue mutations in HIV-1-infected patients [J].
Flandre, P ;
Descamps, D ;
Joly, V ;
Meiffrédy, V ;
Tamalet, C ;
Izopet, J ;
Brun-Vézinet, F .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (05) :862-870
[4]  
Flandre P, 2003, ANTIVIR THER, V8, P65
[5]   A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection [J].
Floridia, M ;
Tomino, C ;
Bucciardini, R ;
Ricciardulli, D ;
Fragola, V ;
Pirillo, MF ;
Amici, R ;
Giannini, G ;
Galluzzo, CM ;
Andreotti, M ;
Seeber, AC ;
Ammassari, A ;
Cingolani, A ;
Lazzarin, A ;
Scalise, G ;
Cargnel, A ;
Suter, F ;
Milazzo, F ;
Pastore, G ;
Moroni, M ;
Ciammarughi, R ;
Pini, R ;
Carosi, G ;
D'Amato, C ;
Contu, L ;
Concia, E ;
Bonazzi, L ;
Aiuti, F ;
Vigevani, G ;
Vella, S .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (17) :1809-1820
[6]   An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine [J].
Hooker, DJ ;
Tachedjian, G ;
Solomon, AE ;
Gurusinghe, AD ;
Land, S ;
Birch, C ;
Anderson, JL ;
Roy, BM ;
Arnold, E ;
Deacon, NJ .
JOURNAL OF VIROLOGY, 1996, 70 (11) :8010-8018
[7]   Evolution of AZT resistance in HIV-1:: The 41-70 intermediate that is not observed in vivo has a replication defect [J].
Jeeninga, RE ;
Keulen, W ;
Boucher, C ;
Sanders, RW ;
Berkhout, B .
VIROLOGY, 2001, 283 (02) :294-305
[8]  
Johnson Victoria A, 2005, Top HIV Med, V13, P51
[9]  
KURITZKES DR, 2004, JAIDS-J ACQ IMM DEF, V36, P600
[10]   Clinically relevant genotype interpretation of resistance to didanosine [J].
Marcelin, AG ;
Flandre, P ;
Pavie, J ;
Schmidely, N ;
Wirden, M ;
Lada, O ;
Chiche, D ;
Molina, JM ;
Calvez, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1739-1744